

AT A GLANCE

NASDAQ: GILD
 Founded: 1987
 HQ: Foster City, CA

\$105.89B
 Market Cap
 (as of 9/29/2017)



9,000
 Employees



Presence in
>30 Countries
 across
6 Continents



4 Primary Therapeutic
 Areas of Focus:

- Antiviral
- Liver Disease
- Oncology
- Inflammation

3Q17 FINANCIALS

PRODUCT REVENUE

\$6.40B

YTD: \$19.83B

NON-GAAP EPS

\$2.27

YTD: \$7.06

OPERATING CASH FLOW

\$2.69B

YTD: \$9.15B



"Cell Design Labs' talented team of cell biology experts will augment and accelerate our work to bring forward new generations of CAR T and TCR therapies, building on our acquisition of Kite earlier this year and our efforts to improve care for people with advanced cancers."

John F. Milligan, PhD
 Gilead's President and
 Chief Executive Officer

SELECTED PIPELINE PRODUCT CANDIDATES

HIV

B/F/TAF

Potential Indications: HIV/AIDS

Phase 1 Phase 2 Phase 3

U.S. and EU Regulatory Submission

Descovy

Potential Indications: PrEP

Liver Diseases

Selonsertib

Potential Indications: NASH

Phase 1 Phase 2 Phase 3

GS-9674

Potential Indications: NASH, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis

GS-0976

Potential Indications: NASH

Hematology / Oncology

Axicabtagene ciloleucel

Potential Indications: DLBCL, PMBCL & TFL

Phase 1 Phase 2 Phase 3

EU Regulatory Submission

KTE-C19

Potential Indications: Adult ALL, Pediatric ALL, Indolent NHL, MCL

KITE-585 (anti-BCMA)

Potential Indications: MM

KITE-718 (MAGE A3/A6)

Potential Indications: Solid Tumor

Andecaliximab (MMP9 mAb inhibitor)

Potential Indications: Gastric Cancer

Inflammation / Respiratory

Filgotinib

Potential Indications: Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis

Phase 1 Phase 2 Phase 3

COMMERCIAL PORTFOLIO HIGHLIGHTS

Human Immunodeficiency Virus (HIV)

Treatment:

Genvoya
 elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg tablets

Odefsey
 emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg tablets

Descovy
 emtricitabine 200mg/tenofovir alafenamide 25mg tablets

Prevention:

Truvada
 emtricitabine-tenofovir disoproxil fumarate

Hepatitis C Virus (HCV)

SOVALDI
 SOFOSBUVIR

HARVONI
 ledipasvir/sofosbuvir 90mg/400mg tablets

EPCLUSA
 sofosbuvir/velpatasvir 400mg/100mg tablets

VOSEVI
 sofosbuvir 400mg/velpatasvir 100mg voxilaprevir 100mg tablets

Hepatitis B Virus (HBV)

Vemlidy
 tenofovir alafenamide 25mg tablets

Oncology

YESCARTA
 axicabtagene ciloleucel

ANALYST COVERAGE

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, BMO, Citi, Cowen & Company, Credit Suisse, Deutsche Bank, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Leerink Partners, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, RBC, Standard and Poors, UBS, Wells Fargo